Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis The global MG Community is turning Awareness into Action ...

Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor ... 24 Myasthenia gravis fact sheet.

SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...

11 National Institute of Neurological Disorders and Stroke. Myasthenia gravis fact sheet. Available at: . Last accessed: April 2025 12 Ye, Yun et al. Epidemiology of myasthenia gravis in the ...

Myasthenia gravis (MG) is a chronic autoimmune condition ... As a result, the most common first MG symptom is ptosis (drooping eyelid). In fact, the majority of people with an MG diagnosis first ...

Excitingly, in myasthenia [gravis], we have entered the advanced therapy era with the approval of the complement inhibitors starting in 2017, and now, more recently, the FcRn [neonatal Fc receptor ...

SPRING HOUSE, Pa., Jan. 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an ...